P
Propanc Biopharma, Inc. (PPCB)
0.10
0.00 (0.00%)
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
0.10
0.00 (0.00%)
Propanc Biopharma, Inc., ishlab chiqish bosqichidagi biotexnologik tibbiyot kompaniyasi, Avstraliyada oshqozon osti bezi, tuxumdon va kolorektal saraton kasalligi bilan og'rigan bemorlar uchun saraton davolashni ishlab chiqish bilan shug'ullanadi. Uning asosiy mahsulot nomzodi PRP bo'lib, bu saratonni davolash va oldini olishda terapevtik variant sifatida ishlab chiqilgan in'ektsiya orqali yuboriladigan proenzimli davolash bo'lib, u preklinik tadqiqotlarni yakunlagan. Kompaniya POP1 dasturi bo'yicha tadqiqot faoliyatini olib borish uchun Xaen universiteti bilan va PRPning sintetik rekombinant versiyasini ishlab chiqish uchun Granada universiteti bilan tadqiqot va hamkorlik to'g'risidagi kelishuvga ega. Propanc Biopharma, Inc. ilgari Propanc Health Group Corporation nomi bilan tanilgan va 2017 yil aprel oyida Propanc Biopharma, Inc. nomini o'zgartirgan. Kompaniya 2007 yilda tashkil etilgan va Avstraliyaning Kambervell shahrida joylashgan.
| Ism | Lavozim |
|---|---|
| Mr. James Nathanielsz | CEO & Executive Chairman |
| Ms. Jeannine Zimmerman | Chief Financial Officer |
| Prof. Klaus Kutz M.D. | Chief Medical Officer & Member of Scientific Advisory Board |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-02-02 | S-1 | forms-1.htm |
| 2026-01-07 | 8-K | form8-k.htm |
| 2025-12-30 | S-1 | forms-1.htm |
| 2025-12-29 | DEF 14C | formdef14c.htm |
| 2025-12-10 | PRE 14C | formpre14c.htm |
| 2025-11-14 | 10-Q | form10-q.htm |
| 2025-11-10 | 8-K | form8-k.htm |
| 2025-10-14 | 8-K | form8-k.htm |
| 2025-09-29 | 10-K | form10-k.htm |
| 2025-08-19 | 8-K | form8-k.htm |